| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1029979011 |
| P356 | DOI | 10.1186/1479-5876-10-217 |
| P932 | PMC publication ID | 3508881 |
| P698 | PubMed publication ID | 23113945 |
| P5875 | ResearchGate publication ID | 232744072 |
| P50 | author | Simon Lovestone | Q30582986 |
| Iwona Kłoszewska | Q38633661 | ||
| Hilkka Soininen | Q38636823 | ||
| Lars-Olof Wahlund | Q38637441 | ||
| Patrizia Mecocci | Q46713839 | ||
| Jane Z. Reed | Q50731852 | ||
| Magda N. Tsolaki | Q57073392 | ||
| Ines Greco | Q58826728 | ||
| Bruno Vellas | Q66877204 | ||
| Christian Spenger | Q114432264 | ||
| Joanna Riddoch-Contreras | Q114432268 | ||
| P2093 | author name string | Andrew Simmons | |
| Julie Barnes | |||
| Nicola Day | |||
| P2860 | cites work | The KUPKB: a novel Web application to access multiomics data on kidney disease | Q28260266 |
| Reorganizing the protein space at the Universal Protein Resource (UniProt) | Q29547338 | ||
| Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease | Q29614881 | ||
| Multivariate analysis of MRI data for Alzheimer's disease, mild cognitive impairment and healthy controls | Q33676329 | ||
| Blood-based biomarkers of Alzheimer's disease: challenging but feasible | Q33824444 | ||
| Cerebrospinal fluid and plasma biomarkers in Alzheimer disease | Q34098866 | ||
| uPAR: a versatile signalling orchestrator | Q34162183 | ||
| Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease | Q35034130 | ||
| Proteome-based plasma markers of brain amyloid-β deposition in non-demented older individuals | Q35076119 | ||
| Proteomics of Alzheimer's disease: understanding mechanisms and seeking biomarkers | Q36787240 | ||
| Elevated C-reactive protein levels are associated with prevalent dementia in the oldest-old | Q37339094 | ||
| Regulation of cell signalling by uPAR. | Q37660895 | ||
| The urokinase receptor: focused cell surface proteolysis, cell adhesion and signaling | Q37663098 | ||
| Biomarkers for Alzheimer's disease therapeutic trials | Q37815749 | ||
| Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species | Q38508018 | ||
| Sialic acid, homocysteine and CRP: potential markers for dementia | Q43274128 | ||
| MRI measures of Alzheimer's disease and the AddNeuroMed study | Q43497894 | ||
| Increased expression of the urokinase plasminogen-activator receptor in amyloid beta peptide-treated human brain microglia and in AD brains | Q43868531 | ||
| Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors. | Q44291669 | ||
| Plasma transthyretin as a candidate marker for Alzheimer's disease | Q44768899 | ||
| A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease | Q46063519 | ||
| Increased CSF-BACE 1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer's disease | Q46707483 | ||
| Amyloid β-Protein Stimulates the Expression of Urokinase-type Plasminogen Activator (uPA) and Its Receptor (uPAR) in Human Cerebrovascular Smooth Muscle Cells | Q48306498 | ||
| Expression of matrix metalloproteinase-9 and urinary-type plasminogen activator in Alzheimer's disease brain | Q48896798 | ||
| AddNeuroMed and ADNI: similar patterns of Alzheimer's atrophy and automated MRI classification accuracy in Europe and North America | Q49041459 | ||
| The role of clusterin, complement receptor 1, and phosphatidylinositol binding clathrin assembly protein in Alzheimer disease risk and cerebrospinal fluid biomarker levels. | Q51605501 | ||
| The AddNeuroMed framework for multi-centre MRI assessment of Alzheimer's disease: experience from the first 24 months. | Q51824464 | ||
| Novel systemic markers for patients with Alzheimer disease? - a pilot study. | Q53296345 | ||
| Is there a relationship between high C-reactive protein (CRP) levels and dementia? | Q53305180 | ||
| AddNeuroMed--the European collaboration for the discovery of novel biomarkers for Alzheimer's disease | Q95800564 | ||
| P921 | main subject | Alzheimer's disease | Q11081 |
| in silico | Q192572 | ||
| biomarker | Q864574 | ||
| P304 | page(s) | 217 | |
| P577 | publication date | 2012-10-31 | |
| P1433 | published in | Journal of Translational Medicine | Q15716664 |
| P1476 | title | Alzheimer's disease biomarker discovery using in silico literature mining and clinical validation | |
| P478 | volume | 10 |
| Q51760901 | A Decade of Blood Biomarkers for Alzheimer's Disease Research: An Evolving Field, Improving Study Designs, and the Challenge of Replication. |
| Q91919314 | A Preliminary Cohort Study Assessing Routine Blood Analyte Levels and Neurological Outcome after Spinal Cord Injury |
| Q48036293 | Advancing Alzheimer's research: A review of big data promises |
| Q33752058 | Circulating biomarkers that predict incident dementia |
| Q47626694 | Current practices and future outlook on the integration of biomarkers in the drug development process |
| Q45934744 | Editorial: Painting by numbers: using modern approaches to analyse and visualise clinical and research data. |
| Q38419506 | Linking hypothetical knowledge patterns to disease molecular signatures for biomarker discovery in Alzheimer's disease |
| Q35811161 | NeuroTransDB: highly curated and structured transcriptomic metadata for neurodegenerative diseases |
| Q39044367 | The developing landscape of diagnostic and prognostic biomarkers for spinal cord injury in cerebrospinal fluid and blood |
| Q38592069 | Translation of Pre-Clinical Studies into Successful Clinical Trials for Alzheimer's Disease: What are the Roadblocks and How Can They Be Overcome? |
Search more.